

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

SUPPLEMENTAL ANNOUNCEMENT DISCLOSEABLE TRANSACTION SUBSCRIPTION OF INTEREST IN LIMITED LIABILITY PARTNERSHIP AND ENTERING INTO THE LIMITED PARTNERSHIP AGREEMENT

Reference is made to the announcement dated 16 April 2024 (the “**Announcement**”) of Fusen Pharmaceutical Company Limited (the “**Company**”) in relation to the discloseable transaction for the subscription of interest in the Limited Liability Partnership and entering into the Limited Partnership Agreement. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board wishes to provide supplemental information in relation to the Limited Partnership Agreement as follows:

While the terms of the Limited Partnership Agreement do not specify the industries in which the Limited Liability Partnership will make investments, the Partners have agreed and confirmed that the Limited Liability Partnership will be engaged in investments business via primarily participating in various potential medical and pharmaceutical related enterprises or projects; in the event that other suitable opportunities arise, the Limited Liability Partnership may also make investments in other industries.

This supplemental announcement is supplemental to and should be read in conjunction with the Announcement. Save as disclosed above, all other information and contents as set out in the Announcement remain unchanged and shall continue to be valid for all purposes.

By order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Changcheng
Chairman and Executive Director

Hong Kong, 16 May 2024

As at the date of this announcement, the Board of the Company comprises Mr. Cao Changcheng (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng, Ms. Meng Qingfen and Mr. Cao Zhiming (formerly known as Mr. Cao Dudu) as executive Directors, and Mr. Sze Wing Chun, Mr. Lee Kwok Tung Louis and Dr. To Kit Wa as independent non-executive Directors.